H.C. Wainwright analyst Edward White maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of $47.00. The company’s shares closed last Monday at $45.77, close to its 52-week high of $46.55.
According to TipRanks.com, White is a top 100 analyst with an average return of 61.2% and a 62.8% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.
Cullinan Management has an analyst consensus of Strong Buy, with a price target consensus of $48.00.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CGEM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cullinan Management Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.